Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Take Five: Who's afraid of U.S. inflation?

04/12/2021 | 03:01am EDT

LONDON, April 12 (Reuters) - 1/ U.S. INFLATION

U.S. consumer prices for March are due out Tuesday and markets are ready to scour the data for signs that massive stimulus spending is spurring inflation. Rising inflation expectations helped ignite a first-quarter selloff in Treasuries that pushed yields to pre-pandemic highs.

A strong reading could spark a fresh jump in yields and be bad news for stocks after the S&P climbed to fresh record highs, especially high-flying growth names.

Fed Chair Jerome Powell said a spending surge as the U.S. economy reopens along with bottlenecks in supply will likely push prices higher this year, but not result in the kind of price rises that would constitute inflation. Analysts see consumer prices rising by a median 2.4% for March year-on-year, up from 1.7% in February.

- Fed's Powell warns on COVID, sees inflation unlikely

2/CHINA GROWTH SPURT

Chinese data on GDP, credit growth, trade, industrial output and retail sales are likely to confirm the narrative of a solidifying economic recovery from pandemic lockdowns.

Economists expect first quarter GDP growth - due out Friday - to rise as much as 20% year-on-year, setting China up for a nearly double-digit 2021 expansion thanks to a resurgence in global manufacturing and a sharp recovery in domestic spending.

But maybe that's too much good news. Investors are fretting policymakers will pedal back on the easy pandemic monetary conditions, and blue chips logged their worst month in a year in March. Premier Li Keqiang has said Beijing will focus instead on consolidating the recovery.

-Chinese premier rejects idea that 2021 GDP growth target too 'low'

3/ GET READY FOR EARNINGS

U.S. corporates - due to kick off the reporting season with the major banks - look on track for the biggest quarterly results gain since Q3 2018, when tax cuts under then President Donald Trump drove a surge in profit growth.

Overall Q1 S&P 500 earnings are expected to have jumped 24.2% from a year earlier, according to IBES data from Refinitiv. The results follow a big rally in sectors including energy and financials - stocks most likely to benefit from the rebound.

A future risk to earnings is the threat of corporate tax rises from 21% currently, as proposed by U.S. President Joe Biden. A 28% tax rate would take 7.4% off S&P 500 companies' earnings per share, UBS estimates.

- PREVIEW-U.S. bank profits may leap, then fade, as investors look under the hood

4/WAITING FOR THE END

The euro area, still deep in lockdowns to combat COVID-19, has had a dose of good news. More than 10 million people in France have now received a first shot of a vaccine, with a government target for the number reached a week ahead of schedule.

Germany's COVID vaccination drive too has picked up speed and Italy, which aims to vaccinate at least 80% of its population by the end of September, could soon sign a contract with Moderna for more vaccine doses.

The vaccine race is key to the reopening of economies and news on this front will remain in focus. The forward-looking PMI indicator also gives reason for hope that economies are coping better than expected with new lockdowns. Euro zone business activity bounced back to growth in March - Germany's ZEW sentiment survey out on Tuesday, may support that picture.

- Euro zone business activity expanded in March despite lockdowns

5/ NEW GOVERNOR, OLD PROBLEMS

Turkey's central bank will hold its first meeting under new governor Sahap Kavcioglu. Since last month's surprise sacking of his predecessor, the lira has plummeted versus the dollar while inflation expectations are rising swiftly.

Policymakers are seen holding interest rates unchanged at 19%, but the expected timeline for a cut has been shortened.

In South America, Sunday elections could confirm a regional leftist turn, giving investors more food for thought.

Ecuador's presidential runoff follows months of debate over whether socialism or market-friendly policies are needed to restart the economy, with a left-wing economist looking in the lead in most polls.

In Peru, polls indicate no clear winner, with six candidates vying for a shot at the June runoff, making the election one of the most unpredictable in recent memory. -POLL-Turkish cenbank to hold rates in new chief's first decision

(Reporting by Dhara Ranasinghe in London, Megan Davies, Caroline Valetkevitch, Ira Iosebashvili and Rodrigo Campos in New York and Vidya Ranganathan in Singapore; compiled by Karin Strohecker; editing by Susan Fenton)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AUSTRALIAN DOLLAR / EURO (AUD/EUR) 0.17% 0.6405 Delayed Quote.1.53%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) 0.73% 0.77796 Delayed Quote.0.37%
BRITISH POUND / EURO (GBP/EUR) -0.24% 1.1602 Delayed Quote.3.94%
BRITISH POUND / US DOLLAR (GBP/USD) 0.34% 1.40928 Delayed Quote.2.72%
CANADIAN DOLLAR / EURO (CAD/EUR) 0.00% 0.680429 Delayed Quote.5.72%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) 0.00% 0.8256 Delayed Quote.4.64%
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.11.16%
EURO / US DOLLAR (EUR/USD) 0.57% 1.21451 Delayed Quote.-1.12%
INDIAN RUPEE / EURO (INR/EUR) 0.00% 0.011239 Delayed Quote.0.58%
INDIAN RUPEE / US DOLLAR (INR/USD) 0.00% 0.013655 Delayed Quote.-0.55%
MODERNA, INC. 7.68% 161.38 Delayed Quote.54.48%
NASDAQ 100 2.17% 13393.115242 Delayed Quote.1.71%
NASDAQ COMP. 2.32% 13429.978403 Delayed Quote.4.20%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) 0.95% 0.72495 Delayed Quote.0.03%
S&P 500 1.49% 4173.85 Delayed Quote.9.49%
UBS GROUP AG 0.65% 13.89 Delayed Quote.11.39%
US DOLLAR / EURO (USD/EUR) -0.56% 0.823377 Delayed Quote.1.13%
All news about MODERNA, INC.
05/15MODERNA  : U.S. CDC Says Administered 270.8 Mln Doses Of COVID-19 Vaccine As Of ..
RE
05/15MODERNA  : U.S. administers 270.8 mln doses of COVID-19 vaccines - CDC
RE
05/14Taiwan tightens curbs after surge in domestic COVID-19 cases
RE
05/14ASTRAZENECA  : Experts call on Canada to use COVAX doses of AstraZeneca or give ..
AQ
05/14Why the CDC Told Fully Vaccinated Americans They Didn't Need to Wear Face Mas..
DJ
05/14MODERNA  : COVID SCIENCE-Delayed 2nd Pfizer/BioNTech shot boosts antibodies in e..
RE
05/14MODERNA  : U.S. administers 268.4 mln doses of COVID-19 vaccines - CDC
RE
05/14MODERNA  : U.S. CDC Says Delivered 341.9 Million Doses Of Covid-19 Vaccine As Of..
RE
05/14PFIZER  : Federal officials lay out road map for post-vaccine life as third wave..
AQ
05/14MODERNA  : The latest news on COVID-19 developments in Canada
AQ
More news
Financials (USD)
Sales 2021 18 363 M - -
Net income 2021 10 203 M - -
Net cash 2021 11 650 M - -
P/E ratio 2021 6,54x
Yield 2021 -
Capitalization 64 799 M 64 799 M -
EV / Sales 2021 2,89x
EV / Sales 2022 2,79x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,60 $
Last Close Price 161,38 $
Spread / Highest target 43,1%
Spread / Average Target 3,23%
Spread / Lowest Target -48,6%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.54.48%64 799
LONZA GROUP AG-0.81%46 408
IQVIA HOLDINGS INC.30.62%44 856
CELLTRION, INC.-24.65%32 736
SEAGEN INC.-15.78%26 768
CUREVAC N.V.35.67%21 497